Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial

American Heart Journal

Volumn 202, Issue , 2018, Pages 89-96

  Berwanger, Otavio ^a   Nicolau, Jose C ^a   Carvalho, Antonio C ^a   Jiang, Lixin ^a   Goodman, Shaun ^a   Nicholls, Stephen J ^a   Parkhomenko, Alexander ^a   Averkov, Oleg ^a   Tajer, Carlos ^a   Malaga, Germán ^a   Kerr Saraiva, Jose F ^a   Fonseca, Francisco ^a   Guimaraes, Helio P ^a   de Barros e Silva, Pedro G M ^a   Damiani, Lucas P ^a   Paisani, Denise M ^a   Lasagno, Camila M R ^a   Candido, Carolina T ^a   Valeis, Nanci ^a   Moia, Diogo D F ^a   Piegas, Leopoldo S ^a   Granger, Christopher B ^a   White, Harvey ^a   Lopes, Renato D ^a   more..

^a Heart Hospital HCOR   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICAGRELOR; ANTICOAGULANT AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ALL CAUSE MORTALITY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; ORGANIZATIONAL STRUCTURE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; INTENTION TO TREAT ANALYSIS; METHODOLOGY; MIDDLE AGED; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTICOAGULANTS; CLOPIDOGREL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESEARCH DESIGN; SINGLE-BLIND METHOD; ST ELEVATION MYOCARDIAL INFARCTION; TICAGRELOR;

EID: 85048718068     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2018.02.017     Document Type: Article

References (18)

1. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127:4 (2013), e362–425.
2. Ibanez, B., James, S., Agewall, S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017 [Epub ahead of print].
3. Vora, A.N., Holmes, D.N., Rokos, I., et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. JAMA Intern Med 175:2 (2015), 207–215.
4. Panduranga, P., Al-Zakwani, I., Sulaiman, K., et al. Clinical Profile and Mortality of ST-Segment Elevation Myocardial Infarction Patients Receiving Thrombolytic Therapy in the Middle East. Heart Views 13:2 (2012), 35–41.
5. Chen, Z.M., Jiang, L.X., Chen, Y.P., et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:9497 (2005), 1607–1621.
6. Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al., for the CLARITY investigators, Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 352:12 (2005), 1179–1189.
7. Curial, M., Nath, E., Lang, E., Novel Antiplatelet Agent Use for Acute Coronary Syndrome in the Emergency Department: A Review. Cardiol Res Pract, 2013, 2013, 127270.
8. O'Connor, Stephen, Montalescot, Gilles, Collet, Jean-Philippe, The P2Y12 receptor as a target of antithrombotic drugs. Purinergic Signal 7:3 (2011), 325–332.
9. Wallentin, L., Becker, R.C., Budaj, A., et al., for the PLATO investigators, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 361 (2009), 1045–1057.
10. Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:19 (2015), 1791–1800.
11. Steg, P.G., James, S., Harrington, R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:21 (2010), 2131–2141.
12. Mehran, R., Rao, S.V., Bhatt, D., et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium. Circulation 123 (2014), 2736–2747.
13. Montalescot, G., van't Hof, Arnoud W., Lapostolle, F., et al., The ATLANTIC Investigators, Phehospital Ticlagrelor in ST-Segment Elevation Myocardial Infarction. N Engl J Med 371 (2014), 1016–1027.
14. Chow, S.-W., Shao, J., Wang, H., Sample Size Calculations in Clinical Research. 2ªed., 2008, Chapman & Hall/CRC, Florida, 106–109 [449 pp. (Statistics Series)].
15. Cantor, W.J., Fitchett, D., Borgundvaag, B., et al., for the TRANSFER-AMI Trial, Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. N Engl J Med 360:26 (2009), 2705–2718.
16. R Core Team, R: A language and environment for statistical computing. 2017, R Foundation for Statistical Computing, Vienna, Austria [URL http://www.R-project.org/].
17. Ohman, E. Magnus, Roe, Matthew T., Gabriel Steg, P., et al., for the Gemini-ACS-1 investigators, Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389 (2017), 1799–1808.
18. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel vs clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.